Halozyme Therapeutics, Inc. - Common Stock (HALO)
103.63
-19.33 (-15.72%)
NASDAQ · Last Trade: Nov 6th, 4:47 PM EST
News & Press Releases
Halozyme (HALO) Q3 2026 Earnings Call Transcriptfool.com
Merck patent setbacks in the U.S. cloud an otherwise strong quarter for royalties.
Via The Motley Fool · November 6, 2026
HALO Q3 2026 deep dive: royalty expansion and next-gen platform investments drive outlook update
Biopharmaceutical drug delivery company Halozyme Therapeutics (NASDAQ:HALO) beat Wall Street’s revenue expectations in Q3 2026, with sales up 39.2% year on y...
Via StockStory · November 6, 2026
What Halozyme Therapeutics (HALO) Said on Its Q3 Earnings Callmarketbeat.com
Halozyme Therapeutics (NASDAQ:HALO) raised its full-year 2026 guidance after reporting record third-quarter revenue and royalties, driven by growth in established partner products and contributions from newer subcutaneous drug launches.
Total revenue rose 39% to $493 million from $354.3 million a y
Via MarketBeat · November 6, 2026
Halozyme Therapeutics (NASDAQ:HALO) Q3 In Line, Guidance Midpoint Below Consensus, Shares Fall After Hourschartmill.com
Via Chartmill · November 5, 2026
Halozyme Therapeutics (NASDAQ:HALO): An Undervalued Value Stock With Strong Profitabilitychartmill.com
Via Chartmill · November 4, 2026
Halozyme Therapeutics (NASDAQ:HALO): A Decent Value Stock With Strong Profitabilitychartmill.com
Via Chartmill · October 9, 2026
Halozyme Therapeutics (NASDAQ:HALO): High Growth Momentum Meets Breakout Setupchartmill.com
Via Chartmill · October 5, 2026
Halozyme Therapeutics (NASDAQ:HALO) Screens Well on High Growth Momentum and Breakout Setupchartmill.com
Via Chartmill · September 9, 2026
Halozyme Therapeutics (NASDAQ:HALO) surprises with Q3 2026 sales but stock drops
Biopharmaceutical drug delivery company Halozyme Therapeutics (NASDAQ:HALO) announced better-than-expected revenue in Q3 2026, with revenue up 39.2% year on ...
Via StockStory · November 5, 2026
Halozyme Therapeutics (HALO) Q3 earnings report preview: what to look for
Biopharmaceutical drug delivery company Halozyme Therapeutics (NASDAQ:HALO) will be announcing earnings results this Thursday after market hours. Here’s what...
Via StockStory · November 3, 2026
2 Reasons to Like HALO (and 1 Not So Much)
Halozyme Therapeutics has been on fire lately. In the past six months alone, the company’s stock price has rocketed 73.5%, reaching $120.69 per share. This w...
Via StockStory · October 19, 2026
1 Unpopular Stock That Deserves a Second Chance and 2 We Brush Off
Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad t...
Via StockStory · October 13, 2026
Halozyme Therapeutics (NASDAQ:HALO) Meets Minervini’s High-Growth Trend Templatechartmill.com
Via Chartmill · August 28, 2026
Halozyme Therapeutics (NASDAQ:HALO) Demonstrates Strong Quality Investing Characteristics Across All Key Metricschartmill.com
Via Chartmill · August 20, 2026
Unpacking Q2 Earnings: Halozyme Therapeutics (NASDAQ:HALO) In The Context Of Other Therapeutics Stocks
Wrapping up Q2 earnings, we look at the numbers and key takeaways for the therapeutics stocks, including Halozyme Therapeutics (NASDAQ:HALO) and its peers. O...
Via StockStory · September 30, 2026
Biogen (NASDAQ:BIIB) Q2 Earnings: Leading The Therapeutics Pack
As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including Bioge...
Via StockStory · September 24, 2026
1 Cash-Producing Stock to Target This Week and 2 We Question
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff...
Via StockStory · September 22, 2026
Argenx Has Delivered 18 Consecutive Quarters of Sales Growth -- but Is the Biotech Stock Still Underrated?fool.com
This biotech innovator could be in only the early chapters of its success story.
Via The Motley Fool · September 2, 2026
1 Mid-Cap Stock on Our Watchlist and 2 We Avoid
Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. Howe...
Via StockStory · August 31, 2026
3 Market-Beating Stocks for Long-Term Investors
Stocks that outperform the market usually share key traits such as rising sales, expanding margins, and increasing returns on capital. The select few that ca...
Via StockStory · August 28, 2026
1 Healthcare Stock with Exciting Potential and 2 We Avoid
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have be...
Via StockStory · August 27, 2026
2 Mid-Cap Stocks with Solid Fundamentals and 1 Facing Challenges
Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. Howe...
Via StockStory · August 24, 2026
Halozyme (HALO) Q2 2026 Earnings Call Transcriptfool.com
Revenue jumped 48% to $481 million on record royalty growth.
Via The Motley Fool · August 13, 2026
The Top 5 Analyst Questions From Halozyme Therapeutics’s Q2 Earnings Call
Halozyme Therapeutics delivered a notably positive second quarter, as evidenced by the strong market reaction and management’s attribution of outperformance ...
Via StockStory · August 13, 2026
HALO Q2 Deep Dive: Royalty Diversification and New Pipeline Drive Upgraded Guidance
Biopharmaceutical drug delivery company Halozyme Therapeutics (NASDAQ:HALO) announced better-than-expected revenue in Q2 CY2026, with sales up 47.7% year on ...
Via StockStory · August 7, 2026